AN4005 for Advanced Cancer
Trial Summary
What is the purpose of this trial?
This trial tests a new drug, AN4005, in patients with advanced tumors. It aims to find the highest safe dose by adjusting the amount given over time.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot take certain drugs that affect liver enzymes (CYP3A4, UGT, P-gP) two weeks before and during the trial. It's best to discuss your current medications with the study team.
Eligibility Criteria
Adults with advanced solid tumors or relapsed/refractory lymphoma, who have no standard treatment options left. They must be expected to live at least 3 months, have a performance status of 0 or 1 (able to carry out daily activities), and meet certain organ function criteria. Pregnant or breastfeeding women are excluded, as well as those with recent infections, vaccinations, other treatments, or severe allergies.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive increasing doses of AN4005 to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)
Treatment
Participants receive AN4005 at the determined MTD/RP2D
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AN4005 (Other)